Continuous Renal Replacement Therapy Market Size by 2030
< br>Perspectivas del mercado y visión del analista:
Este informe incluye perspectivas de crecimiento debido a las tendencias actuales del mercado de la terapia de reemplazo renal continuo y su impacto previsible durante el período de pronóstico.
Terapia de reemplazo renal continuo (CRRT) ) es una intervención que salva vidas para pacientes que sufren lesión renal aguda (IRA) grave, sobrecarga de líquidos y uremia con anomalías metabólicas potencialmente mortales. Factores como la mayor demanda de dispositivos CRRT pediátricos y la alta prevalencia de enfermedades crónicas que conducen a enfermedades renales impulsan el crecimiento continuo del mercado de la terapia de reemplazo renal. Sin embargo, una posibilidad significativa de que se produzca un evento renal adverso importante (MAKE) limita el crecimiento del mercado.
Impulsores del mercado:
Alta incidencia de enfermedades crónicas que conducen a enfermedades renales
1 Una de cada 10 personas en todo el mundo se ve afectada por la enfermedad renal crónica (ERC), que es una afección común y potencialmente mortal. De 2015 a 2019, la diabetes y la presión arterial alta fueron las dos causas principales de insuficiencia renal en el 75% del total de casos de insuficiencia. Según estimaciones publicadas por la Fundación Nacional del Riñón en 2020, en los EE. UU. ~30 % de la población diabética mayor de 20 años tiene riesgo de desarrollar ERC durante su vida. Además, esta enfermedad causó más muertes que el cáncer de próstata o el cáncer de mama en 2020, y es un trastorno sanitario de emergencia poco reconocido. 1 de cada 3 adultos estadounidenses (es decir, ~80 millones de personas) tiene riesgo de ERC, que ahora se identifica como un claro factor de riesgo de IRA. La disminución de la tasa de filtración glomerular (TFG) y el aumento de la proteinuria están fuertemente asociados con una IRA.
Según el Instituto Nacional de Salud, la aparición de IRA está aumentando en los países desarrollados. Se prevé que su prevalencia en pacientes hospitalizados alcance el 15% y que sea mayor en pacientes críticamente enfermos, es decir, el 60%. La incidencia de IRA en pacientes hospitalizados en todo el mundo oscila entre el 0,7% y el 31%; Los pacientes en unidades de cuidados intensivos (UCI) experimentan una incidencia superior al 50%. Un rango del 3% al 13% de los pacientes con IRA necesitan TRR y se estima que el 40% de estos pacientes necesitan CRRT durante más de 90 días. Por lo tanto, la alta prevalencia de enfermedades crónicas que conducen a enfermedades renales impulsa el crecimiento continuo del mercado de la terapia de reemplazo renal.
Los principales efectos nocivos asociados con la CRRT incluyen hipotensión, taquicardia y otras arritmias, que pueden afectar negativamente la condición del paciente o impedir su recuperación. Además, el circuito CRRT podría facilitar una eliminación más rápida de micronutrientes, oligoelementos y/o medicamentos terapéuticos, lo que puede provocar concentraciones bajas o irregulares en la sangre y los tejidos, provocando así efectos adversos y/o pérdida del efecto terapéutico. Por lo tanto, los efectos adversos restringen el mercado de la terapia de reemplazo renal continuo.
Segmentación y alcance del informe:
El análisis del mercado de la terapia de reemplazo renal continuo ha sido llevado a cabo por considerando los siguientes segmentos: producto, modalidad y usuario final.
Análisis segmentario:
El mercado de terapia de reemplazo renal continua, por producto, se segmenta en dializados y líquidos de reemplazo, desechables, conjuntos de líneas sanguíneas. y tubos, sistemas CRRT y hemofiltros. El segmento de sistemas CRRT representó la mayor participación del mercado en 2022. Se prevé que el segmento de hemofiltros registre la CAGR más alta del mercado durante 2022-2030.
Mercado de terapia de reemplazo renal continua, por producto – 2022 y 2030
Por modalidad, el mercado de terapia de reemplazo renal continuo se segmenta en hemofiltración venovenosa continua (CVVH), hemodiafiltración venovenosa continua (CVVHDF), hemodiálisis venovenosa continua (CVVHD) y ultrafiltración continua lenta (SCUF). El segmento de hemofiltración venovenosa continua (CVVH) tuvo la mayor participación de mercado en 2022. Se espera que el mercado para el segmento de hemodiafiltración venovenosa continua (CVVHDF) registre la CAGR más alta durante 2022-2030.
Por usuario final , el mercado de la terapia de reemplazo renal continuo se segmenta en hospitales, centros de atención ambulatoria, atención domiciliaria y otros. En 2022, el segmento de hospitales dominó la cuota de mercado de la terapia de reemplazo renal continua. Sin embargo, se espera que el segmento de monitorización domiciliaria registre la CAGR más alta durante 2022-2030.
Análisis regional:
El alcance del informe de mercado de terapia de reemplazo renal continuo abarca América del Norte (EE. UU., Canadá y México), Europa (España, Reino Unido, Alemania, Francia, Italia y resto de Europa), Asia Pacífico (Corea del Sur, China, India, Japón, Australia y resto de Asia Pacífico), Medio Oriente y África (Sur África, Arabia Saudita, Emiratos Árabes Unidos y el resto de Oriente Medio y África) y América del Sur y Central (Brasil, Argentina y el resto de América del Sur y Central).
En términos de ingresos, en 2022, Norte Estados Unidos dominó la cuota de mercado de la terapia de reemplazo renal continuo. Se prevé que el mercado de Asia Pacífico registre la CAGR más alta durante 2022-2030. El mercado de la terapia de reemplazo renal continuo en Asia Pacífico está creciendo con la mejora de la infraestructura sanitaria y la adopción de tecnologías CRRT innovadoras, las cuales pueden asociarse con un aumento del gasto sanitario. Además, las iniciativas estratégicas de los actores del mercado para ampliar su presencia en Asia Pacífico, como las colaboraciones con proveedores de atención médica locales, favorecen el crecimiento del mercado en la región.
Panorama competitivo y empresas clave:
El informe de mercado de terapia de reemplazo renal continuo se centra en actores destacados del mercado como Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica SpA, Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA. y Quanta Dialysis Technologies Inc. El pronóstico del mercado de terapia de reemplazo renal continuo puede ayudar a las partes interesadas a planificar sus estrategias de crecimiento. Estas empresas se centran en lanzar nuevas tecnologías, actualizar productos existentes y expandir sus negocios para satisfacer la creciente demanda de los consumidores en todo el mundo.
En abril de 2022, la Administración de Alimentos y Medicamentos de EE. UU. (FDA) otorgó la autorización 510(k) para el ST Set de Baxter International Inc. para su uso en terapia de reemplazo renal continua (CRRT). El ST Set es un circuito extracorpóreo (fuera del cuerpo) desechable, preconectado, que proporciona purificación de la sangre a través de una membrana semipermeable para usarse con las unidades de control (monitores) PrisMax o Prismaflex. En marzo de 2022, Nipro Medical Corporation (Nipro) , fabricante y proveedor líder de productos renales, vasculares y médico-quirúrgicos, anunció el lanzamiento comercial del sistema de hemodiálisis SURDIAL DX en EE. UU. SURDIAL DX es un sistema de hemodiálisis de última generación diseñado para crear una experiencia de tratamiento de diálisis óptima para pacientes y médicos. Fabricado en Japón, el producto se basa en más de 35 años de experiencia en innovación de dispositivos renales en la empresa matriz de Nipro, Nipro Corporation.
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Continuous renal replacement therapy is an available renal replacement method that includes intermittent hemodialysis and peritoneal dialysis to provide renal support for critically ill patients with acute kidney injury, mainly patients who are hemodynamically unstable. It is intended to be applied for 24 hours or longer through continuous, slower dialysis. CRRT is performed through pump-driven venovenous extracorporeal circuits and acts as renal support through blood purification to allow solute and fluid homeostasis.
The continuous renal replacement therapy market majorly consists of players such as Baxter International Inc, Asahi Kasei, Fresenius Medical Care, Medica S.p.A., Medtronic Plc, B. Braun, Nikkiso Co Ltd, Toray Medical Co Ltd, Infomed SA, and Quanta Dialysis Technologies Inc.
US holds the largest market share in continuous renal replacement therapy market According to the Centers for Disease Control and Prevention in 2021, ~785,000 people in the US were living with end-stage kidney disease also known as end-stage renal disease; 71% out of these were undergoing dialysis while 29% had undergone kidney transplant procedures. As of 2020, there were nearly 7,500 dialysis clinics in the US. The increasing adoption of unhealthy food habits is one of the most prominent risk factor for numerous lifestyle-related disorders such as hypertension, diabetes, and kidney dysfunction.
The factors that are driving the growth of the market are the increased demand for pediatric CRRT devices and the high prevalence of chronic diseases leading to kidney diseases.
The continuous renal replacement therapy market, based on product, is segmented into dialysates and replacement fluids, disposables, bloodline sets and tubes, CRRT systems, and hemofilters. The CRRT systems segment held the largest share of the market in 2022.
The continuous renal replacement therapy market, based on modality, is continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF), continuous venovenous hemodialysis (CVVHD), and slow continuous ultrafiltration (SCUF). The continuous venovenous hemofiltration (CVVH) segment held the largest share of the market in 2022; however, the continuous venovenous hemodiafiltration (CVVHDF) segment is likely to register the highest CAGR.
Asia Pacific is expected to be the fastest-growing region in the continuous renal replacement therapy market. Improving healthcare infrastructure with rising expenditure and the adoption of innovative CRRT technologies bolster the continuous renal replacement therapy market size in Asia Pacific. Additionally, strategic initiatives by the market players to expand their presence in this region, including collaborations with local healthcare providers, favor the market growth in the region.
The continuous renal replacement therapy market, based on end user, is segmented into hospitals, ambulatory care centers, home care, and others. In 2022, the hospitals segment dominated the continuous renal replacement therapy market share. The home monitoring segment is expected to register the highest CAGR during 2022–2030.
The List of Companies - Continuous Renal Replacement Therapy Market
- Baxter International Inc
- Asahi Kasei
- Fresenius Medical Care
- Medica S.p.A.
- Medtronic Plc
- B. Braun
- Nikkiso Co Ltd
- Toray Medical Co Ltd
- Infomed SA
- Quanta Dialysis Technologies Inc
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For